| Date | Phase | Anouncement | Biotech | Pharma | Product | Disease | Country | Other |
|---|---|---|---|---|---|---|---|---|
| 2010-04-23 | II | Launch | Affiris (Austria) | vaccine candidate AD02 | Alzheimer disease | Austria, Germany, France, the Czech Republic, Slovakia and Croatia | See details | |
| 2010-04-21 | II | Result | MolMed (Italy) | NGR-hTNF (vascular targeting agent) | malignant pleural mesothelioma | See details | ||
| 2010-04-21 | II | Result | Swedish Orphan Biovitrum (Sweden) | enzyme replacement therapy to improve growth and development in preterm | enzyme replacement therapy to improve growth and development in preterm infants receiving pasteurized breast milk and/or formula | See details | ||
| 2010-04-20 | Other | Result | ThromboGenics (Belgium) | microplasmin | non surgical treatment of back of the eye disease | See details | ||
| 2010-04-19 | I-IIa | Launch | Ark Therapeutics (UK) | EG016 - (AD-VEGF D/adenoviral short-form Vascular Endothelial Growth Factor D gene construct) | peripheral vascular disease | Finland | See details | |
| 2010-04-15 | Other | Result | Active Biotech (Sweden) | Teva Pharmaceutical (Israel) | laquinimod | relapsing remitting multiple sclerosis (RRMS) | See details | |
| 2010-04-15 | IIa | Result | Kenta Biotech (Switzerland) | panobacumab (KBPA101 - fully human IgM monoclonal antibody) | hospital-acquired pneumonia and ventilator-acquired pneumonia caused by P. aeruginosa | See details | ||
| 2010-04-15 | III | Result | Sanofi-aventis | lixisenatide (AVE 0010 - once-daily GLP-1 agonist) | type 2 diabetes | See details | ||
| 2010-04-14 | II | Launch | Crucell (The Netherlands) Aeras Global TB Vaccine Foundation | Ad35-AERAS-402 (AdVac®-based tuberculosis vaccine) | tuberculosis | South Africa | See details | |
| 2010-04-13 | III | Launch | MolMed (Italy) | NGR-hTNF (vascular targeting agent) | malignant pleural mesothelioma | See details | ||
| 2010-04-13 | III | Result | Novartis (Switzerland) | Gilenia® (FTY720 - fingolimod) | multiple sclerosis | See details | ||
| 2010-04-12 | I | Result | Nabriva Therapeutics (Austria) | BC-3781 (pleuromutilin antibiotic) | skin and skin structure infections, community-acquired pneumonia | See details | ||
| 2010-04-12 | I-IIa | Launch | SuppreMol (Germany) | SM101 (recombinant soluble non-glycosylated version of the Fc-receptor FcyRIIb) | idiopathic thrombocytopenic purpura | Germany, Belgium, Poland, and Russia | See details | |
| 2010-04-07 | I-II | Launch | Neovacs (France) | IFN alpha-Kinoid® (IFN-K) | lupus | France, Belgium an other European countries | See details | |
| 2010-03-30 | I-II | Launch | Prosensa (The Netherlands) | PRO044 | Duchenne Muscular Dystrophy | Belgium, Italy, Sweden | See details |
